Frontier Biotechnologies Inc
SSE:688221
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (31.8), the stock would be worth ¥12.4 (42% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 55.2 | ¥21.5 |
0%
|
| 3-Year Average | 31.8 | ¥12.4 |
-42%
|
| 5-Year Average | 35.5 | ¥13.84 |
-36%
|
| Industry Average | 10.3 | ¥4.01 |
-81%
|
| Country Average | 3.3 | ¥1.29 |
-94%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
¥7.4B
|
/ |
Oct 2025
¥141.2m
|
= |
|
|
¥7.4B
|
/ |
Dec 2025
¥162.6m
|
= |
|
|
¥7.4B
|
/ |
Dec 2026
¥191.9m
|
= |
|
|
¥7.4B
|
/ |
Dec 2027
¥208.4m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
F
|
Frontier Biotechnologies Inc
SSE:688221
|
8.1B CNY | 55.2 | -48 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
349.5B USD | 6.6 | 83.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183B USD | 6.1 | 23.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
160.4B USD | 5.8 | 18.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 8.4 | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.3B USD | 3.9 | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 10.4 | 36.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.1B AUD | 3.3 | 29.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.7 |
| Median | 3.3 |
| 70th Percentile | 6.2 |
| Max | 5 034 353.9 |
Other Multiples
Frontier Biotechnologies Inc
Glance View
Frontier Biotechnologies, Inc. engages in the research and development, production, and sale of medicines. The company is headquartered in Nanjing, Jiangsu and currently employs 495 full-time employees. The company went IPO on 2020-10-28. The firm's products include Aikening and Combination regiment of Albuvirtide (ABT) + 3BNC117 which is during clinical stage for treatment of human immunodeficiency virus (HIV). Its clinical-stage products also include transdermal analgesic patch AB001 for treating muscle, skeleton and joint pain. The firm conducts its businesses within the China market and to overseas markets.
